International Journal of Clinical Pharmacy

, Volume 35, Issue 4, pp 550–553 | Cite as

Use of monoclonal antibodies for metastatic colorectal cancer in the andalusian public health system

  • Bernardo Santos-RamosEmail author
  • Rocío Fernández-Fernández
  • Roberto Marín-Gil
  • María Espinosa-Bosch
  • Salvador Peiró-Moreno
  • Concepción Pérez-Guerrero
  • Javier Bautista-Paloma
Short Research Report


Background The place of monoclonal antibodies in metastatic colorectal cancer has not been clearly defined. Objective To determine the treatment pattern of monoclonal antibodies in colorectal cancer patients in the Andalusian Public Healthcare System. Method Data were collected from all patients treated with these drugs from July 2009 to December 2010 from pharmacy programs and medical records. Results Three hundred patients were included, of whom 227 received the antibody at the forefront. The proportion of patients who received bevacizumab in the first line is greater than that of cetuximab (62.1 vs. 37.5 % respectively) and similar in the second line and subsequent (47.8 vs. 53.8 % and 48.5 vs. 46.2 % respectively). XELOXbevacizumab was the most frequently prescribed scheme (35.3 %) followed by FOLFOX-monoclonal antibody schemes, regardless that this was bevacizumab or cetuximab (22.5 %). The median progression free survival (PFS) was 11.7 months for patients receiving cetuximab, 9.6 months for patients receiving bevacizumab and 8.2 months for those who received no monoclonal antibody in the first line. Conclusion Bevacizumab was the antibody of choice in first line, showing utilization rates similar to cetuximab in second line and subsequent. The median PFS in our study is related to the PFS of the major clinical trials.


Bevacizumab Cetuximab Colorectal cancer Drug utilization Panitumumab 



All pharmacists who have collaborated on the project: Garrido MT, Garrido M, Vallejo I, Martínez MJ, Martínez C, Mora B, Gavira R, Jimenez R, Nieto F, Garrido R, García-Pelayo N, Muñoz N, Gordillo E, Marín JF, Mora MA, Férnandez JJ, Zaragoza M, Muro B, Nacle I, Gago AI, Damas M.


This study was supported by the Health Department of the Spanish Government. (Investigación Clínica Independiente. Ministerio de Sanidad y Política Social).

Conflicts of interest

The authors declare that they have no conflicts of interest.


  1. 1.
    Corral MJ, Clopés A, Navarro M, Germà JR, Borràs JM. Impact on budget of new drugs for colorectal cancer treatment. Med Clin (Barc). 2007;129:134–7.CrossRefGoogle Scholar
  2. 2.
    Hess GP, Wang PF, Quach D, Barber B, Zhao Z. Systemic therapy for metastatic colorectal cancer: patterns of chemotherapy and biologic therapy use in US medical oncology practice. J Oncol Pract. 2010;6:301–7.PubMedCrossRefGoogle Scholar
  3. 3.
    Zhao Z, Pelletier E, Barber B, Bhosle M, Wang S, Gao S, et al. Patterns of treatment with chemotherapy and monoclonal antibodies for metastatic colorectal cancer in Western Europe. Curr Med Res Opin. 2012;28:221–9.PubMedCrossRefGoogle Scholar
  4. 4.
    Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004;22:229–37.PubMedCrossRefGoogle Scholar
  5. 5.
    Colucci G, Gebbia V, Paoletti G, Giuliani F, Caruso M, Gebbia N, et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell’Italia Meridionale. J Clin Oncol. 2005;23:4866–75.PubMedCrossRefGoogle Scholar
  6. 6.
    Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26:2013–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Fuchs CS, Marshall J, Mitchell E, Wierzbicki R, Ganju V, Jeffery M, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol. 2007;25:4779–86.PubMedCrossRefGoogle Scholar
  8. 8.
    Van Cutsem E, Köhne CH, Lang I, Folprecht G, Nowacki MP, Cascinu S, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol. 2011;29:2011–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Sargent DJ, Köhne CH, Sanoff HK, Bot BM, Seymour MT, de Gramont A, et al. Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer. J Clin Oncol. 2009;27:1948–55.PubMedCrossRefGoogle Scholar
  10. 10.
    Kozloff M, Yood MU, Berlin J, Flynn PJ, Kabbinavar FF, Purdie DM, et al. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. Oncologist. 2009;14:862–70.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2013

Authors and Affiliations

  • Bernardo Santos-Ramos
    • 1
    Email author
  • Rocío Fernández-Fernández
    • 1
  • Roberto Marín-Gil
    • 2
  • María Espinosa-Bosch
    • 1
  • Salvador Peiró-Moreno
    • 3
  • Concepción Pérez-Guerrero
    • 4
  • Javier Bautista-Paloma
    • 1
  1. 1.Unidad de Gestión Clínica Farmacia HospitalariaHospital Universitario Virgen del RocíoSevillaSpain
  2. 2.Subdirección de Farmacia y PrestacionesServicio Andaluz de SaludSevillaSpain
  3. 3.Centro Superior de Investigación en Salud Pública (CSISP)ValenciaSpain
  4. 4.Departamento de FarmacologíaFacultad de FarmaciaSevillaSpain

Personalised recommendations